Methylphenidate sustained release - DURECT

Drug Profile

Methylphenidate sustained release - DURECT

Alternative Names: ORADUR-Methylphenidate ER; ORADUR-ADHD; ORADUR-Methylphenidate

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator DURECT Corporation
  • Developer DURECT Corporation; Orient Pharma
  • Class Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Central nervous system stimulants; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Attention-deficit hyperactivity disorder

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder

Most Recent Events

  • 08 Aug 2017 Positive efficacy and adverse events data from a phase III trial in Attention deficit hyperactivity disorder released by DURECT Corporation
  • 10 May 2017 Orient Pharma completes enrolment in its phase III trial for Attention-deficit hyperactivity disorder in Taiwan
  • 01 Jun 2015 Phase-III clinical trials in Attention-deficit hyperactivity disorder (In children, In adolescents) in Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top